Vitae Pharmaceuticals (NASDAQ: VTAE) and MediWound (NASDAQ:MDWD) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Valuation & Earnings

This table compares Vitae Pharmaceuticals and MediWound’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Vitae Pharmaceuticals N/A N/A N/A ($1.93) -10.88
MediWound $2.17 million 59.51 -$16.18 million ($0.75) -6.53

Vitae Pharmaceuticals has higher revenue, but lower earnings than MediWound. Vitae Pharmaceuticals is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Vitae Pharmaceuticals has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500. Comparatively, MediWound has a beta of 0.06, suggesting that its stock price is 94% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for Vitae Pharmaceuticals and MediWound, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vitae Pharmaceuticals 0 0 0 0 N/A
MediWound 0 0 5 0 3.00

MediWound has a consensus target price of $10.00, suggesting a potential upside of 104.08%. Given MediWound’s higher possible upside, analysts clearly believe MediWound is more favorable than Vitae Pharmaceuticals.

Institutional and Insider Ownership

72.6% of Vitae Pharmaceuticals shares are held by institutional investors. Comparatively, 19.5% of MediWound shares are held by institutional investors. 14.8% of Vitae Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Vitae Pharmaceuticals and MediWound’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Vitae Pharmaceuticals -318,350.20% -53.70% -49.85%
MediWound -752.78% -326.32% -48.65%

Summary

MediWound beats Vitae Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

Vitae Pharmaceuticals Company Profile

Vitae Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company’s product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders. The Company completed approximately two Phase I studies with VTP-43742. Its VTP-38543, a second product candidate is in a Phase IIa proof-of-concept clinical trial for the treatment of atopic dermatitis. Its VTP-36951 is for the treatment and prevention of Alzheimer’s disease, or Alzheimer’s. VTP-43742, the Company’s wholly owned clinical candidate in an on-going Phase IIa proof-of-concept trial in psoriasis, is an orally active small molecule inhibitor of Retinoic acid-receptor (RAR)-Related Orphan Receptor gamma-t (RORgt) activity for the treatment of various autoimmune disorders.

MediWound Company Profile

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.

Receive News & Ratings for Vitae Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitae Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.